Cargando…
Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature
Bone and joint infections (BJIs) caused by multidrug-resistant gram-negative bacteria are becoming a concern due to limited therapeutic options. Although not approved for these indications, an ever-growing amount of evidence supports the efficacy and safety of ceftazidime–avibactam as a therapy for...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451286/ https://www.ncbi.nlm.nih.gov/pubmed/37627748 http://dx.doi.org/10.3390/antibiotics12081328 |
_version_ | 1785095402020667392 |
---|---|
author | Mancuso, Alessandro Pipitò, Luca Rubino, Raffaella Distefano, Salvatore Antonino Mangione, Donatella Cascio, Antonio |
author_facet | Mancuso, Alessandro Pipitò, Luca Rubino, Raffaella Distefano, Salvatore Antonino Mangione, Donatella Cascio, Antonio |
author_sort | Mancuso, Alessandro |
collection | PubMed |
description | Bone and joint infections (BJIs) caused by multidrug-resistant gram-negative bacteria are becoming a concern due to limited therapeutic options. Although not approved for these indications, an ever-growing amount of evidence supports the efficacy and safety of ceftazidime–avibactam as a therapy for osteomyelitis and prosthetic joint infections. Here, we present three cases of difficult-to-treat resistant Pseudomonas aeruginosa osteomyelitis that were successfully treated with ceftazidime–avibactam alone or in combination therapy with fosfomycin and amikacin. Ceftazidime–avibactam was prescribed at a daily dose of 2.5 g every 8 h for 42 days in all cases. One potential drug-related adverse effect was observed, i.e., Clostridioides difficile infection, which occurred after fourteen days of treatment with ceftazidime–avibactam. |
format | Online Article Text |
id | pubmed-10451286 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104512862023-08-26 Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature Mancuso, Alessandro Pipitò, Luca Rubino, Raffaella Distefano, Salvatore Antonino Mangione, Donatella Cascio, Antonio Antibiotics (Basel) Case Report Bone and joint infections (BJIs) caused by multidrug-resistant gram-negative bacteria are becoming a concern due to limited therapeutic options. Although not approved for these indications, an ever-growing amount of evidence supports the efficacy and safety of ceftazidime–avibactam as a therapy for osteomyelitis and prosthetic joint infections. Here, we present three cases of difficult-to-treat resistant Pseudomonas aeruginosa osteomyelitis that were successfully treated with ceftazidime–avibactam alone or in combination therapy with fosfomycin and amikacin. Ceftazidime–avibactam was prescribed at a daily dose of 2.5 g every 8 h for 42 days in all cases. One potential drug-related adverse effect was observed, i.e., Clostridioides difficile infection, which occurred after fourteen days of treatment with ceftazidime–avibactam. MDPI 2023-08-17 /pmc/articles/PMC10451286/ /pubmed/37627748 http://dx.doi.org/10.3390/antibiotics12081328 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Mancuso, Alessandro Pipitò, Luca Rubino, Raffaella Distefano, Salvatore Antonino Mangione, Donatella Cascio, Antonio Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature |
title | Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature |
title_full | Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature |
title_fullStr | Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature |
title_full_unstemmed | Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature |
title_short | Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature |
title_sort | ceftazidime-avibactam as osteomyelitis therapy: a miniseries and review of the literature |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451286/ https://www.ncbi.nlm.nih.gov/pubmed/37627748 http://dx.doi.org/10.3390/antibiotics12081328 |
work_keys_str_mv | AT mancusoalessandro ceftazidimeavibactamasosteomyelitistherapyaminiseriesandreviewoftheliterature AT pipitoluca ceftazidimeavibactamasosteomyelitistherapyaminiseriesandreviewoftheliterature AT rubinoraffaella ceftazidimeavibactamasosteomyelitistherapyaminiseriesandreviewoftheliterature AT distefanosalvatoreantonino ceftazidimeavibactamasosteomyelitistherapyaminiseriesandreviewoftheliterature AT mangionedonatella ceftazidimeavibactamasosteomyelitistherapyaminiseriesandreviewoftheliterature AT cascioantonio ceftazidimeavibactamasosteomyelitistherapyaminiseriesandreviewoftheliterature |